| Literature DB >> 31792370 |
Qinyuan Zhu1, Yanzhou Zhang2, Jiekun Xuan3, Fanping Yang1, Binbin Du2, Sheng-An Chen1, Sijia Yan4, Menglin Jiang4, Huizhong Zhu4, Hao Xiong1, Xiaoqun Luo5, Qinghe Xing6.
Abstract
Tanshinone, a widely used Chinese patent medicine, has been confirmed to have various kinds of pharmacological effects although frequently causing cutaneous adverse drug reactions (cADRs). We aim to identify whether human leukocyte antigen (HLA) class I alleles are associated with tanshinone-induced cADRs in Han Chinese. The association study including 18 patients with tanshinone-induced cADRs, 67 tanshinone-tolerant volunteers, and two general population databases consisted of 10,689 and 169,995 healthy subjects was performed. The frequency of tanshinone-induced cADRs patients carrying HLA-A*02:01 was significantly higher when compared with the general control groups (OR = 6.25, Pc = 7.20 × 10-5; OR = 7.14, Pc = 8.00 × 10-6), and with the tolerant group (OR = 5.09, Pc = 0.024). The molecular docking assay confirmed high affinity of the ingredients of tanshinone towards HLA-A*02:01 (≤-7.5 kcal/mol). The result suggested HLA-A*02:01 may work as a promisingly predictive marker for tanshinone personalized therapy in Han Chinese.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31792370 DOI: 10.1038/s41397-019-0121-1
Source DB: PubMed Journal: Pharmacogenomics J ISSN: 1470-269X Impact factor: 3.550